Molecule AI is revolutionising drug discovery by using artificial intelligence to predict molecular combinations and ...

New FDA guidelines for personalized genomic drug development are a step forward in advancing new therapies for ultrarare diseases, but industry leaders need further clarification.

In this week’s edition of InnovationRx, we look at cheaper biologic drugs, Novo Nordisk’s $2 billion next-gen obesity drug deal, new ways of fighting cancer, and more.

Overview Artificial intelligence seems to be transforming drug discovery in 2026, enabling faster molecule design, smarter clinical trials, and reduced R&D ...

Rare Disease Day is held on the last day of February to raise awareness for rare diseases and address drug development ...

Experience the forefront of pharmaceutical innovation as Labroots and the Drug Discovery and Development planning committee host the 9th Annual Drug Discovery & Development Virtual Event on February ...

Rare genetic diseases such as ataxia telangiectasia and cystic fibrosis lack strong commercial incentives, prompting ...

The FDA has opened the door to the use of Bayesian statistical methods in clinical trials. The worry: Introducing ...

Clinical trials are not just about testing medicines; they are about building the future of healthcare There is a dire need ...

Innovators are increasingly focused on whether outsourced partners can help them make better decisions earlier, before ...

Explore SLAS Boston 2026 insights on connecting laboratory automation and data infrastructure in drug discovery workflows.